07.01.2013 Views

Sorted By Test Name - Mayo Medical Laboratories

Sorted By Test Name - Mayo Medical Laboratories

Sorted By Test Name - Mayo Medical Laboratories

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

MMLSA<br />

56031<br />

MACCL<br />

89218<br />

antimicrobial therapy. <strong>Mayo</strong> Clin Proc 1998;73:1007-1021<br />

Antimicrobial Susceptibility, Anaerobic Bacteria, MIC<br />

Clinical Information: Anaerobic bacteria make up a large part of the human bodyâ€s normal flora<br />

and generally do not cause infection. When usual skin and mucosal barriers are penetrated and in an<br />

anaerobic environment, they can behave as pathogens. Anaerobes grow aggressively in the body under<br />

anaerobic conditions and may possess a variety of virulence factors including capsules and extracellular<br />

enzymes. They also can develop resistance to antimicrobials by producing beta-lactamase and other<br />

modifying enzymes and by alterations in membrane permeability and structure of penicillin-binding<br />

proteins. Because anaerobic bacteria are a significant cause of human infection and they are often resistant<br />

to commonly used antimicrobials, susceptibility testing results are useful to clinicians. The following<br />

antimicrobials are routinely tested for the various groups of anaerobes. Anaerobic gram-negative bacilli<br />

Beta-lactamase positive Piperacillin/tazobactam, ertapenem, metronidazole, clindamycin Beta-lactamase<br />

negative Penicillin, clindamycin, metronidazole Anaerobic cocci and nonsporeforming gram-positive<br />

bacilli, Clostridium perfringens Penicillin, clindamycin, metronidazole Clostridium species other than<br />

Clostridium perfringens Penicillin, clindamycin, metronidazole, ertapenem, piperacillin/tazobactam<br />

Propionibacterium species Penicillin, moxifloxacin, minocycline Actinomyces species Penicillin,<br />

clindamycin Additionally, the following antimicrobials may be individually requested or added to the<br />

above panels: -Amoxicillin/clavulanic acid, ceftriaxone, meropenem, ciprofloxacin, and vancomycin<br />

Useful For: Directing antimicrobial therapy for anaerobic infections<br />

Interpretation: Minimal inhibitory concentration (MIC) and interpretive category (susceptible,<br />

intermediate, or resistant) results are reported. Note that vancomycin, ciprofloxacin, and minocycline will<br />

have no interpretation attached to the MIC. Resistant results indicate an organism is resistant to the<br />

antimicrobial tested and that the agent should not be used for treatment. Intermediate results indicate that<br />

treatment with high doses might well be successful. Susceptible results indicate that therapy with usual<br />

doses is appropriate.<br />

Reference Values:<br />

Minimum inhibitory concentration (MIC) results are reported in mcg/mL with an interpretation of<br />

S-susceptible, R-resistant, or I-intermediate. Vancomycin, ciprofloxacin, and minocycline are reported as<br />

MIC values only (without interpretation).<br />

Clinical References: Rosenblatt JE, Brook I: Clinical relevance of susceptibility testing of anaerobic<br />

bacteria. Clin Infect Dis 1993;16(Suppl 4):S446-S448<br />

Antimicrobial Susceptibility, Mycobacterium avium Complex,<br />

Clarithromycin<br />

Clinical Information: Mycobacterium avium complex (MAC) organisms are the most common<br />

environmental mycobacteria causing human disease. Clinical presentation can include pulmonary disease,<br />

lymphadenitis, and disseminated disease. The Clinical Laboratory Standards Institute (CLSI), the<br />

American Thoracic Society (ATS), and the Infectious Diseases Society of America (IDSA) recommend<br />

that MAC isolated from previously untreated patients should be tested for susceptibility to clarithromycin<br />

because this drug acts as the class agent for the newer macrolides and shares cross-resistance with<br />

azithromycin. Clarithromycin susceptibility testing should also be performed for MAC isolates from<br />

patients who fail macrolide therapy or prophylaxis. <strong>Test</strong>ing of other drugs for MAC is not recommended<br />

by the CLSI or ATS/IDSA because no correlation has been established between in vitro susceptibility<br />

testing and clinical response to agents other than macrolides.<br />

Useful For: Determining resistance of Mycobacterium avium complex to clarithromycin<br />

Interpretation: Using broth microdilution at pH 7.3 to 7.4, a clarithromycin minimum inhibitory<br />

concentration (MIC) of < or =8 mcg/mL is susceptible, a MIC=16 mcg/mL is intermediate, and a MIC ><br />

or =32 mcg/mL is resistant.<br />

Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or <strong>Mayo</strong><strong>Medical</strong><strong>Laboratories</strong>.com Page 152

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!